XTNT Xtant Medical Holdings Inc

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2019.

Third Quarter 2019 Financial Highlights and Recent Announcements:

• Revenue for the third quarter of 2019 was $15.7 million, compared to $17.3 million for the same prior year period
• Operating expenses in the third quarter of 2019 were $11.2 million, compared to $13.0 million for the same prior year period
• Net loss incurred in the third quarter of 2019 was $1.9 million, compared to a net loss of $3.2 million for the same prior year period
• Non-GAAP Adjusted EBITDA for the third quarter of 2019 was $0.6 million, compared to $1.8 million for the same prior year period
• Board of Directors appoints Sean Browne President and Chief Executive Officer effective October 7, 2019 and a member of the Board effective October 30, 2019

Sean Browne, President and CEO of Xtant Medical, said, “After my first month with Xtant, I am excited about the Company, our unique products and dedicated employees. I am pleased with our efforts and results over the past three quarters enhancing the operational effectiveness of our business.  We remain committed to continuing to develop and release new products, expand our marketing programs, and pursue operational improvements intended to assist us in our overall commercial performance.”

Third Quarter 2019 Financial Results

Third quarter 2019 revenue was $15.7 million, compared to $17.3 million for the same period in 2018. This decrease was due primarily to reduced demand for hardware products, which was attributable in part to the termination of an advisory agreement with an entity that provided services to certain customers, and the continued transition of independent sales agents.

Gross margin for the third quarter of 2019 was 66.6%, which was comparable to the same period in 2018.

Operating expenses for the third quarter of 2019 were $11.2 million, compared to $13.0 million for the third quarter of 2018, a decrease of 13.7%. The decrease was primarily attributable to lower sales commissions and travel expenses, restructuring expenses incurred during the year-ago period, and a decrease in amortization expense related to the impairment of intangible assets that occurred in the fourth quarter of 2018, which were partially offset by higher general and administrative expenses.

Third quarter 2019 net loss was $1.9 million, or $0.14 per share, compared to third quarter 2018 net loss of $3.2 million, or $0.24 per share.

Non-GAAP Adjusted EBITDA for the third quarter of 2019 was $0.6 million compared to $1.8 million for the same period of 2018. The Company defines non-GAAP Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on accounts receivable and inventory, non-cash compensation, changes in warrant derivative liability, field action expenses, separation related expenses, litigation reserves, and restructuring expenses. A calculation and reconciliation of non-GAAP Adjusted EBITDA to net loss can be found in the attached financial tables.

Conference Call

Xtant Medical will host a webcast and conference call to discuss the third quarter 2019 financial results on Thursday, November 7, 2019 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Important Cautions Regarding Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential” similar expressions or the negative thereof, and the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase or maintain revenue, including the success of the Company’s initiatives to stabilize and increase revenues; the ability to remain competitive; the ability to innovate and develop new products; the effect of recent management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to retain and recruit independent sales agents and the impact of the termination of a consulting agreement with an entity that had close relationships with several of customers; the ability to service Company debt and comply with debt covenants; the ability to raise additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission (SEC) on April 1, 2019 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David CareyLazar FINN PartnersPh: 212-867-1762Email: david.carey@finnpartners.com

XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except number of shares and par value)
		As of September 30, 2019				As of December 31, 2018
ASSETS
Current Assets:
Cash and cash equivalents		$	5,749			$	6,797
Trade accounts receivable, net of allowance for doubtful accounts of $1,375 and $2,140, respectively			9,121				9,990
Inventories			16,025				17,301
Prepaid and other current assets			714				589
Total current assets			31,609				34,677
Property and equipment, net			5,068				7,174
Right-of -use asset, net			2,198				-
Goodwill			3,205				3,205
Intangible assets, net			529				573
Other assets			428				793
Total Assets		$	43,037			$	46,422
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities:
Accounts payable		$	2,249			$	6,465
Accrued liabilities			6,196				5,150
Warrant derivative liability			17				10
Current portion of lease liability			387				-
Current portion of financing lease obligations			229				426
Total current liabilities			9,078				12,051
Long-term Liabilities:
Lease liability, less current portion			1,827				-
Financing lease obligation, less current portion			6				204
Long-term debt, less issuance costs			74,985				77,939
Total Liabilities			85,896				90,194
Stockholders' Equity (Deficit)
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock, $0.000001 par value; 50,000,000 shares authorized; 13,161,762 shares issued and outstanding as of September 30, 2019 and 13,172,179 shares issued and outstanding as of December 31, 2018			-				-
Additional paid-in capital			178,802				171,273
Accumulated deficit			(221,661	)			(215,045	)
Total Stockholders’ Equity (Deficit)			(42,859	)			(43,772	)
Total Liabilities & Stockholders’ Equity (Deficit)		$	43,037			$	46,422

XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except number of shares and per share amounts)
		Three Months Ended September30,								Nine Months Ended September 30,
			2019				2018				2019				2018
Revenue
Orthopedic product sales		$	15,691			$	17,139			$	47,574			$	53,622
Other revenue			30				127				144				319
Total revenue			15,721				17,266				47,718				53,941
Cost of sales			5,249				5,743				16,527				17,711
Gross profit			10,472				11,523				31,191				36,230
Gross profit %			66.6	%			66.7	%			65.4	%			67.2	%
Operating expenses
General and administrative			4,155				3,121				12,513				10,006
Sales and marketing			6,682				7,847				19,496				24,742
Research and development			203				347				675				1,179
Depreciation and amortization			137				1,029				442				3,074
Restructuring expenses			-				614				-				2,582
Total operating expenses			11,177				12,958				33,126				41,583
Loss from operations			(705	)			(1,435	)			(1,935	)			(5,353	)
Other (expense) income
Interest expense			(1,185	)			(1,790	)			(4,504	)			(8,156	)
Change in warrant derivative liability			4				42				(8	)			83
Other (expense) income			30				30				(101	)			18
Total Other (Expense) Income			(1,151	)			(1,718	)			(4,613	)			(8,055	)
Net Loss from Operations Before Provision for Income Taxes			(1,856	)			(3,153	)			(6,548	)			(13,408	)
Provision for income taxes
Current and deferred			(23	)			-				(68	)			-
Net Loss from Operations		$	(1,879	)		$	(3,153	)		$	(6,616	)		$	(13,408	)
Net loss per share:
Basic		$	(0.14	)		$	(0.24	)		$	(0.50	)		$	(1.19	)
Dilutive		$	(0.14	)		$	(0.24	)		$	(0.50	)		$	(1.19	)
Shares used in the computation:
Basic			13,161,762				13,158,326				13,164,694				11,262,642
Dilutive			13,161,762				13,158,326				13,164,694				11,262,642

XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
	Nine Months Ended September 30,
		2019				2018
Operating activities:
Net loss	$	(6,616	)		$	(13,408	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		2,338				4,943
Gain on disposal of fixed assets		(27	)			(15	)
Non-cash interest		4,467				7,853
Non-cash rent expense		16				-
Non-cash stock option expense / change in derivative warrant liability		263				502
Provision for losses on accounts receivable and inventory		970				298
Changes in operating assets and liabilities:
Accounts receivable		417				2,842
Inventories		760				(508	)
Prepaid and other assets		240				1,138
Accounts payable		(4,216	)			(3,557	)
Accrued liabilities		1,046				(867	)
Net cash provided by operating activities		(342	)			(779	)
Investing activities:
Purchases of property and equipment and intangible assets		(403	)			(308	)
Proceeds from sale of fixed assets		241				251
Net cash used in investing activities		(162	)			(57	)
Financing activities:
Payments on financing leases		(395	)			(260	)
Costs associated with either loan or equity transactions		(149	)			-
Costs associated with private placement and convertible debt exchange		-				(3,507	)
Proceeds from equity private placement		-				6,810
Proceeds from issuance of stock		-				1
Net cash (used in) provided by financing activities		(544	)			3,044
Net change in cash and cash equivalents		(1,048	)			2,208
Cash and cash equivalents at beginning of period		6,797				2,856
Cash and cash equivalents at end of period	$	5,749			$	5,064

XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(Unaudited, in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2019				2018				2019				2018
Net Loss		$	(1,879	)		$	(3,153	)		$	(6,616	)		$	(13,408	)
Other expense			(30	)			(30	)			101				(18	)
Depreciation and amortization			779				1,655				2,338				4,943
Interest expense			1,185				1,790				4,504				8,156
Tax expense			23				-				68				-
Non-GAAP EBITDA			78				262				395				(327	)
Non-GAAP EBITDA/Total revenue			0.5	%			1.5	%			0.8	%			-0.6	%
NON-GAAP ADJUSTED EBITDA CALCULATION
Provision for losses on accounts receivable and inventory			220				312				970				296
Non-cash compensation			95				41				256				585
Change in warrant derivative liability			(4	)			(42	)			8				(83	)
Separation-related expenses			-				566				-				2,535
Field action expenses			182				-				307				-
Litigation reserve			-				-				800				-
Restructuring expenses			-				614				-				2,582
Non-GAAP Adjusted EBITDA		$	571			$	1,753			$	2,736			$	5,588
Non-GAAP Adjusted EBITDA/Total revenue			3.6	%			10.2	%			5.7	%			10.4	%